Understanding Familial Hypercholesterolemia
An inherited disorder of LDL cholesterol metabolism that causes markedly elevated cholesterol from birth and significantly increases the risk of early cardiovascular disease without treatment.
- Inherited Lipid Disorder
- Early Cardiovascular Risk
- Lifelong Cholesterol Management
- Access to Advanced Lipid-Lowering Therapies
- Heterozygous FH Prevalence
- ~1 in 250 people
- Homozygous FH Prevalence
- ~1 in 160,000-300,000
- Inheritance Pattern
- Autosomal dominant (mostly)
- Advanced Therapies
- PCSK9 Inhibitors, Lipoprotein Apheresis, Gene-Targeted Agents
Condition Overview
Familial hypercholesterolemia (FH) is an inherited disorder that impairs the body's ability to clear low-density lipoprotein (LDL) cholesterol from the bloodstream. As a result, LDL cholesterol levels are markedly elevated from birth, leading to premature buildup of cholesterol in artery walls.
Most cases follow an autosomal dominant pattern, meaning a single altered copy of a gene such as LDLR, APOB, or PCSK9 is enough to cause disease. A rarer, more severe form, homozygous FH, occurs when both gene copies are affected and is associated with extremely high cholesterol levels and very early-onset cardiovascular disease.
Because FH is common and often underdiagnosed, early identification through cholesterol screening and family history review is critical to starting treatment before significant arterial damage occurs.
Genetic Subtypes
FH is classified by inheritance pattern and the specific gene involved, which influences severity and treatment approach.
Symptoms and Signs
Many people with FH have no symptoms until a cardiovascular event occurs, which is why screening and family history are so important.
Causes and Risk Factors
FH is caused by inherited mutations affecting how the body processes LDL cholesterol, with additional factors influencing overall cardiovascular risk.
Diagnosis and Investigations
Diagnosis relies on cholesterol levels, clinical findings, family history, and, increasingly, genetic testing.
Risk Stratification
FH is not staged like a malignancy, but risk is generally stratified by genotype, LDL level, and presence of established cardiovascular disease.
Standard Treatment Options
Treatment aims to lower LDL cholesterol as much as possible to reduce lifetime cardiovascular risk, generally starting early and continuing for life.
Advanced and Emerging Treatment Options
For patients with severe or treatment-resistant FH, particularly homozygous FH, additional advanced options are available or under investigation.
Targeted Biologic
PCSK9 Inhibitors (e.g. evolocumab, alirocumab)
Monoclonal antibodies that block PCSK9, increasing LDL receptor availability and substantially lowering LDL cholesterol.
RNA-Based Therapy
Inclisiran (siRNA targeting PCSK9)
A twice-yearly injectable that reduces PCSK9 production, offering durable LDL lowering with infrequent dosing.
Apheresis
Lipoprotein apheresis
A procedure that mechanically filters LDL particles from the blood, used in severe homozygous FH or treatment-resistant cases.
Targeted Therapy
Lomitapide / Evinacumab
Agents that act through alternative lipid-lowering pathways and are used specifically in homozygous FH when standard therapies are insufficient.
Gene Therapy
Investigational gene-based approaches
Early-stage research is exploring gene editing and gene transfer strategies aimed at restoring LDL receptor function.
Biomarkers and Precision Medicine
Lipid and genetic markers guide diagnosis, risk stratification, and treatment selection in FH.
When a Second Opinion May Be Important
Several scenarios in FH management benefit from specialist lipid clinic or cardiology review.
Clinical Trials and Research
Prognosis and Key Outcome Factors
With early diagnosis and consistent LDL-lowering treatment, many people with FH can substantially reduce their cardiovascular risk and approach outcomes similar to the general population; without treatment, risk of early cardiovascular events is significantly elevated.
Supportive Care and Living With Familial Hypercholesterolemia
Living with FH involves long-term lifestyle habits, medication adherence, and regular monitoring to protect cardiovascular health.
How CancerFax Helps You Explore Treatment Options
CancerFax can help you organize your lipid panel and genetic test results, coordinate a second opinion with a lipid specialist or cardiologist, and connect you with centers experienced in advanced therapies such as PCSK9 inhibitors and lipoprotein apheresis.
Get a free case reviewFrequently Asked Questions
Familial hypercholesterolemia is an inherited disorder that causes markedly elevated LDL cholesterol from birth, increasing the risk of early cardiovascular disease if untreated.
Many people have no symptoms initially; clues can include very high cholesterol on routine testing, tendon xanthomas, corneal arcus, or a family history of early heart disease.
Diagnosis combines fasting lipid panels, clinical examination, family history, standardized clinical scoring systems, and often genetic testing.
There is no cure, but LDL cholesterol can usually be substantially lowered with lifestyle changes and medications, greatly reducing cardiovascular risk.
Most forms of FH are autosomal dominant, meaning each child of an affected parent has roughly a 50% chance of inheriting the condition. Genetic counseling can clarify individual risk.
Heterozygous FH involves one altered gene copy and is more common, while homozygous FH involves two altered copies and causes much higher cholesterol and earlier cardiovascular disease.
Untreated FH significantly increases the risk of early heart attacks, strokes, and other cardiovascular events, sometimes starting in young adulthood or even childhood in severe cases.
Yes. PCSK9 inhibitors, siRNA-based therapies, and other targeted agents have expanded options, particularly for people who don't reach LDL targets with statins alone.
Cascade screening of first-degree relatives is recommended, since identifying FH early in family members allows treatment to start before cardiovascular disease develops.
Yes. CancerFax can help you organize your lipid and genetic test reports, facilitate a second opinion with a lipid specialist or cardiologist, and coordinate access to centers offering advanced therapies such as PCSK9 inhibitors and apheresis.
Get Support Managing Familial Hypercholesterolemia
Connect with lipid specialists and cardiologists experienced in advanced cholesterol-lowering therapies.